BioMensio
Biomensio is a highly innovative biotechnology company specializing in scalable multiplexing Lab-on-a-chip devices for rapid on-site diagnostics. Their mission is to develop point-of-need applications for food quality monitoring, mobile diagnostics for healthcare, and drugs of abuse detection, leveraging biofunctionalization methods to enable widespread adoption of sensing technologies. The company aims to transform traditional manufacturing systems in Europe through biologization of micro-manufacturing and advancing biosensor technology.
Industries
Nr. of Employees
small (1-50)
BioMensio
Biomensio Ltd, Hermiankatu 6-8 H, FI-33720 TAMPERE, Finland
Patents
Device and method for detecting a substance using a thin film resonator (FBAR) having an insulating layer
US-9046464-B2
View Details
Device and method for detecting a substance using a thin film resonator (FBAR) having an insulating layer
US-9046464-B2
View DetailsProducts
Handheld multianalyte biosensor system
A portable detection system combining a handheld reader and disposable fluidic cartridges that uses mass-sensitive microarray sensors to provide label-free, multiplexed detection from small liquid samples with local display and cloud/API data export.
Disposable fluidic cartridges for multiplex assays
Cost-efficient, cartridge-format fluidics that house the mass-sensitive microarray sensor and enable rapid sample introduction and automated measurement in the handheld reader.
Handheld multianalyte biosensor system
A portable detection system combining a handheld reader and disposable fluidic cartridges that uses mass-sensitive microarray sensors to provide label-free, multiplexed detection from small liquid samples with local display and cloud/API data export.
Disposable fluidic cartridges for multiplex assays
Cost-efficient, cartridge-format fluidics that house the mass-sensitive microarray sensor and enable rapid sample introduction and automated measurement in the handheld reader.
Services
Collaborative development of multiplexed assays for on-site detection (food safety, drugs-of-abuse, pathogens, inflammatory biomarkers) optimized for handheld mass-sensitive microarray platforms.
Execution and support of pilot deployments and field demonstrations for screening applications (for example antibiotic residue screening in raw milk and roadside drug screening pilots).
Collaborative development of multiplexed assays for on-site detection (food safety, drugs-of-abuse, pathogens, inflammatory biomarkers) optimized for handheld mass-sensitive microarray platforms.
Execution and support of pilot deployments and field demonstrations for screening applications (for example antibiotic residue screening in raw milk and roadside drug screening pilots).
Expertise Areas
- Point-of-need diagnostics
- Multiplexed biosensing
- Label-free kinetic detection
- MEMS and wafer-scale sensor manufacturing
Key Technologies
- Mass-sensitive microarray sensors
- Bulk acoustic wave sensors / SMR transducers
- Label-free real-time binding analysis
- Disposable fluidic cartridges (lab-on-a-chip)
News & Updates
The project will discuss ways to prevent viral infectious diseases indoors to keep society viable during pandemics. It is funded by Business Finland with a total budget of EUR 12 million and will last for 2.5 years.
Funding will support the roadmap for commercial scale manufacturing of Biomensio’s biosensor. The round is organized in Finland, with a maximum size of 3 million Euros.
Funding will support the development of the biosensor platform. The round is organized in Finland, with a maximum size of 5 million Euros.
Biomensio received a grant from the EU SME Instrument Phase II for developing a device to detect intoxication by illicit drugs, supporting the scaling of silicon-based biosensors.
The project aims to develop innovative technologies in microsensor manufacturing, enabling the scale-up of silicon-based biosensors and transforming the semiconductor industry in Europe.
Biomensio was recognized as a winner at the Falling Walls Venture 2021, a platform for leaders in science, business, politics, arts, and society.
The project will discuss ways to prevent viral infectious diseases indoors to keep society viable during pandemics. It is funded by Business Finland with a total budget of EUR 12 million and will last for 2.5 years.
Funding will support the roadmap for commercial scale manufacturing of Biomensio’s biosensor. The round is organized in Finland, with a maximum size of 3 million Euros.
Funding will support the development of the biosensor platform. The round is organized in Finland, with a maximum size of 5 million Euros.
Biomensio received a grant from the EU SME Instrument Phase II for developing a device to detect intoxication by illicit drugs, supporting the scaling of silicon-based biosensors.
The project aims to develop innovative technologies in microsensor manufacturing, enabling the scale-up of silicon-based biosensors and transforming the semiconductor industry in Europe.
Biomensio was recognized as a winner at the Falling Walls Venture 2021, a platform for leaders in science, business, politics, arts, and society.